CRISPR Stocks List

Related ETFs - A few ETFs which own one or more of the above listed CRISPR stocks.

CRISPR Stocks Recent News

Date Stock Title
May 3 CRSP CRISPR Therapeutics AG (CRSP) Outperforms Broader Market: What You Need to Know
May 3 CRSP Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)
May 3 NTLA IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
May 3 ABEO Abeona Therapeutics prices its $75M offering; shares rise
May 3 ABEO Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
May 3 CVAC Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates
May 2 ABEO Buying The Dip In Abeona Therapeutics After The Recent Manufacturing-Related CRL
May 2 MGX J.P. Morgan downgrades Metagenomi over Moderna deal termination
May 2 NTLA Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
May 2 CRSP 3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
May 2 EDIT Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
May 1 MGX Metagenomi, Moderna terminate gene editing collaboration
May 1 MGX Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems
May 1 EDIT Editas, Bristol Myers extend T cell therapy collaboration
May 1 CRSP Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock
May 1 EDIT Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Apr 30 CRSP Invest In A Revolutionary Gene Therapy With CRISPR Therapeutics
Apr 30 RPTX Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition
Apr 30 RPTX Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
Apr 29 EDIT 12 Under-the-Radar Stocks With Massive Upside for 2024
CRISPR

CRISPR () (clustered regularly interspaced short palindromic repeats) is a family of DNA sequences found within the genomes of prokaryotic organisms such as bacteria and archaea. These sequences are derived from DNA fragments from viruses that have previously infected the prokaryote and are used to detect and destroy DNA from similar viruses during subsequent infections. Hence these sequences play a key role in the antiviral defense system of prokaryotes.Cas9 (or "CRISPR-associated 9") is an enzyme that uses CRISPR sequences as a guide to recognize and cleave specific strands of DNA that are complementary to the CRISPR sequence. Cas9 enzymes together with CRISPR sequences form the basis of a technology known as CRISPR/Cas9 that can be used to edit genes within organisms. This type of gene editing process has a wide variety of applications including use as a basic biology research tool, development of biotechnology products, and potentially to treat diseases..

The CRISPR/Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages that provides a form of acquired immunity. RNA harboring the spacer sequence helps Cas (CRISPR-associated) proteins recognize and cut foreign pathogenic DNA. Other RNA-guided Cas proteins cut foreign RNA. CRISPR are found in approximately 50% of sequenced bacterial genomes and nearly 90% of sequenced archaea.

Browse All Tags